Home ADNKronos Dragonfly Therapeutics Announces All Rights Revert to Dragonfly for DF6002, its Proprietary IL12 Investigational Immunotherapy Program
 

Immediapress

Dragonfly Therapeutics Announces All Rights Revert to Dragonfly for DF6002, its Proprietary IL12 Investigational Immunotherapy Program

 

(Adnkronos) - Dragonfly now wholly owns the IL12 cytokine, currently in mid-Phase 1 dose escalation as a monotherapy and in combination with nivolumab. Dragonfly's IL12 was designed to combine well with a broad range of oncology agents including radiatio

I contenuti di VeneziePost sono a pagamento.
Per visualizzare questo articolo e tutti i nostri contenuti scegli tra queste opzioni
Sei già iscritto a VeneziePost?
Clicca qui sotto e inserisci le tue credenziali
Accedi
Facebook Twitter Linkedin Email